{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005090,73,MONDO:0005090,14,2]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0005090","source":"MONDO:0005090|schizophrenia","targets":["NCT00000374|Treatment for First-Episode Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00001656|Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders|COMPLETED|PHASE4|INTERVENTIONAL","NCT00007774|To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00014001|CATIE- Schizophrenia Trial|COMPLETED|PHASE4|INTERVENTIONAL","NCT00018668|Antipsychotic Response in Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00034801|Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00034905|A Comparison of Seroquel vs. Risperidone in Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00036088|Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00044187|The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00044655|Switching Medication to Treat Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00048828|Treating Drug-Resistant Childhood Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00053703|Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00056498|Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine|COMPLETED|PHASE4|INTERVENTIONAL","NCT00061802|Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00080327|Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00088049|Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00090012|Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00100776|Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00103571|Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00108368|The Effects of Risperidone and Olanzapine on Thinking|COMPLETED|PHASE4|INTERVENTIONAL","NCT00114595|Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00130923|Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00137020|Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00140166|Treatment of Acute Schizophrenia With Vitamin Therapy|COMPLETED|PHASE4|INTERVENTIONAL","NCT00145847|Naltrexone Treatment of Alcohol Abuse in Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00148564|Energy Homeostasis Under Treatment With Atypical Antipsychotics|COMPLETED|PHASE4|INTERVENTIONAL","NCT00156715|Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00158223|Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00159081|One Year Drug Treatment in First-Episode Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00159120|Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00159133|Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00159757|12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients|TERMINATED|PHASE4|INTERVENTIONAL","NCT00167817|Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT00169026|Alcoholism and Schizophrenia: Effects of Clozapine|TERMINATED|PHASE4|INTERVENTIONAL","NCT00169039|Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia|TERMINATED|PHASE4|INTERVENTIONAL","NCT00169065|Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00169091|Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia|TERMINATED|PHASE4|INTERVENTIONAL","NCT00176423|Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00176436|Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00177008|Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety|COMPLETED|PHASE4|INTERVENTIONAL","NCT00177580|Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin|COMPLETED|PHASE4|INTERVENTIONAL","NCT00182442|Cognition, Functioning and Quality of Life|COMPLETED|PHASE4|INTERVENTIONAL","NCT00182494|Diabetes Prevention Program in Schizophrenia [DPPS]|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00183625|Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00186771|Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00190749|Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00191555|Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment|COMPLETED|PHASE4|INTERVENTIONAL","NCT00194025|Valproate in Late Life Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00199940|Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness|COMPLETED|PHASE4|INTERVENTIONAL","NCT00202293|Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features|COMPLETED|PHASE4|INTERVENTIONAL","NCT00202306|Indicated Prevention of Psychotic Disorders With Low-dose Lithium|COMPLETED|PHASE4|INTERVENTIONAL","NCT00203788|Improving Work Outcome in People With Recent-onset Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00204061|Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00205660|Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole|COMPLETED|PHASE4|INTERVENTIONAL","NCT00206102|A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00208143|Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00208169|Abilify Therapy for Reducing Comorbid Substance Abuse|COMPLETED|PHASE4|INTERVENTIONAL","NCT00214578|Seroquel on Glucose Metabolism|COMPLETED|PHASE4|INTERVENTIONAL","NCT00215579|Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence|COMPLETED|PHASE4|INTERVENTIONAL","NCT00216528|A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres|COMPLETED|PHASE4|INTERVENTIONAL","NCT00216632|A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00216671|Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode|COMPLETED|PHASE4|INTERVENTIONAL","NCT00220714|PREvent First Episode Relapse (PREFER)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00222794|A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00224822|The Effects of Aripiprazole on Patients With Metabolic Syndrome|COMPLETED|PHASE4|INTERVENTIONAL","NCT00231335|Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00231894|Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00232349|Efficacy of Galantamine to Treat Schizophrenia|TERMINATED|PHASE4|INTERVENTIONAL","NCT00232687|A Switch Study of BMS-337039 in Schizophrenic Out-patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00236379|A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00237861|Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00239109|Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00245206|Side Effects of Newer Antipsychotics in Older Adults|COMPLETED|PHASE4|INTERVENTIONAL","NCT00245674|SOLIACS: Solian Solution in the Acute Setting|COMPLETED|PHASE4|INTERVENTIONAL","NCT00246259|A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00249171|A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00249288|Folate Supplementation in Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00253110|A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder|COMPLETED|PHASE4|INTERVENTIONAL","NCT00254241|Safety and Efficacy of Seroquel in First Episode Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00255515|Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00256997|A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication|TERMINATED|PHASE4|INTERVENTIONAL","NCT00261430|A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00269919|An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00272597|Risperidone LA Heathcare Resource Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT00287820|Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism|COMPLETED|PHASE4|INTERVENTIONAL","NCT00289861|Risperidone Augmentation in Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00290121|Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics|COMPLETED|PHASE4|INTERVENTIONAL","NCT00295412|The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00299702|Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00300846|A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00303602|Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00304616|SWitching to Abilify Trial (SWAT)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00304655|Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00305474|Identification and Treatment of the Liability to Develop Schizophrenia|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00306475|Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?|COMPLETED|PHASE4|INTERVENTIONAL","NCT00307203|Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke|COMPLETED|PHASE4|INTERVENTIONAL","NCT00308360|Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility|COMPLETED|PHASE4|INTERVENTIONAL","NCT00313391|Risperdal Consta and Health Care Utilization in Patients With Schizophrenia|COMPLETED|PHASE4|INTERVENTIONAL","NCT00314327|Optimizing Response in Psychosis Study|TERMINATED|PHASE4|INTERVENTIONAL","NCT00314613|Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal|TERMINATED|PHASE4|INTERVENTIONAL"]}]}